Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
Top Cited Papers
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Regulatory Peptides
- Vol. 117 (2) , 77-88
- https://doi.org/10.1016/j.regpep.2003.10.028
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell ApoptosisJournal of Biological Chemistry, 2003
- Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1Drug Development Research, 2001
- Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic MiceJournal of Biological Chemistry, 2000
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999
- Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and TreatmentJournal of Clinical Endocrinology & Metabolism, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Interaction of GLP-I and Leptin at Rat Pancreatic B-Cells: Effects on Insulin Secretion and Signal TransductionHormone and Metabolic Research, 1997
- Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanismsReproduction Nutrition Development, 1996
- U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study GroupDiabetes, 1995
- Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptorDiabetes, 1993